<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974686</url>
  </required_header>
  <id_info>
    <org_study_id>201603167</org_study_id>
    <secondary_id>CRAD001AUS209T</secondary_id>
    <nct_id>NCT02974686</nct_id>
  </id_info>
  <brief_title>Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation</brief_title>
  <official_title>Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who receive renal transplantation at BJH are placed on triple maintenance
      immunosuppression, which means that patients take 3 types of immunosuppression drugs to
      suppress their immune system including tacrolimus, mycophenolate (MPA), and prednisone.
      However, due to the effects of MPA on the gastrointestinal tract, patients often complain of
      GI adverse effects. Current practice is to either dose-reduce MPA or convert the patient to
      an alternative agent, typically Azathioprine. Both of these strategies have limitations,
      largely due to concerns related to efficacy. Everolimus (EVR) has demonstrated similar
      efficacy to MPA in renal transplantation and may offer a benefit related to GI adverse
      effects, so the investigators will convert patients to EVR in this study. Patients who are
      within their first year post-transplant will be converted to EVR upon enrollment in the
      study, and serial measurements ,or a series of measurements looking for an increase or
      decrease over time, of GI adverse effects will be conducted over 1 year post-enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>1, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Proven Acute Rejection</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Gastrointestinal Disorder, Functional</condition>
  <arm_group>
    <arm_group_label>Interventional (EVR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Agent (MPA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will have baseline data collected while on MPA for comparison with EVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Interventional (EVR)</arm_group_label>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid</intervention_name>
    <arm_group_label>Prior Agent (MPA)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Kidney transplant recipients at Washington University/Barnes-Jewish Hospital

          2. Experiencing GI toxicity from MPA as determined by the treating physician within 12
             months post-renal transplant

          3. On standard immunosuppression with tacrolimus and prednisone

        Exclusion Criteria:

          1. Dual organ or kidney after another solid organ transplant

          2. Presence of a preexisting significant GI condition that does not have a presumed
             causal relationship with MPA

          3. Evidence of any GI disorder induced by an infection, underlying medical condition, or
             concomitant medication other than MPA

          4. eGFR&lt;40 ml/min at time of possible conversion

          5. Proteinuria &gt;1 gram/day at time of possible conversion

          6. Profound bone marrow suppression at the time of possible conversion as defined as:

               -  Hemoglobin &lt;10 g/dL

               -  WBC &lt;3 K/cumm

               -  Platelets &lt;100 K/cumm

          7. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound
             infection, incisional hernia, lymphocele, seroma)

          8. Elevated total cholesterol (&gt;350 mg/dL) and/or triglycerides (&gt;500 ng/dL) at time of
             possible conversion

          9. Hypersensitivity to everolimus, sirolimus, or other rapamycin deriviatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rowena Delos Santos, MD</last_name>
    <email>delossantos@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Hagopian, PharmD</last_name>
    <email>jennifer.hagopian@bjc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Delos Santos, MD</last_name>
      <phone>314-362-4547</phone>
      <email>delossantos@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Rowena Delos Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Horwedel, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Hagopian, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

